Novavax (NVAX) earnings report Q4 2023


Shares of Novavax closed more than 20% lower on Wednesday after the vaccine maker reported fourth-quarter revenue and earnings that missed Wall Street’s estimates and said it expects full-year 2024 sales to come in flat or lower than last year.

Still, Novavax narrowed its losses in the quarter from the same period a year ago, even as demand for the biotech company’s Covid vaccine – its only marketable product – and other shots and treatments that combat the virus continue to plummet worldwide. 

Here’s what Novavax reported for the fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv:

  • Loss per share: $1.44 vs. a…

Source cnbc.com

0 0 votes
Article Rating

Paramount Global (PARA) earnings Q4 2023

Previous article

Cava stock pops after blunder leads to early earnings release

Next article

You may also like

Notify of
Inline Feedbacks
View all comments

More in Earnings